Italy's Alfasigma to buy drugmaker Intercept for nearly $800 mln (updated)

Intercept Pharmaceuticals

26/09/2023 13:27

(Adds details from the release in paragraph 3)
       Sept 26 (Reuters) - Italy's Alfasigma S.p.A said on
Tuesday it had agreed to buy U.S. drugmaker Intercept
Pharmaceuticals  ICPT.O  for $794 million to expand its presence
in the United States.
    Alfasigma will pay $19 per Intercept share, which represents
a premium of 82% to its last closing price.
    With this deal, expected to close by the end of the year,
Alfasigma aims to expand its treatment portfolio related to
liver diseases and digestive system disorders.

 (Reporting by Manas Mishra and Pratik Jain in Bengaluru;
Editing by Shilpi Majumdar)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15;))